Health Canada approves new therapy Jascayd (nerandomilast) for adults with IPF and PPF, offering an option to slow lung ...
Mobility issues have prompted columnist Sam Kirton to downsize, but he will miss the lakefront house that he and his wife called home.
Cold and flu season can be stressful with PF, so columnist Kylene Henderson plans ahead so her family can still enjoy the ...
Oral therapy admilparant slowed lung function decline in people with idiopathic pulmonary fibrosis (IPF) in a Phase 3 ...
Columnist Ann Reynoso pays tribute to a special respiratory therapist who guided her during her pulmonary rehabilitation ...
Columnist Sam Kirton recalls some of the scariest moments since his IPF diagnosis, and invites readers to share their own experiences.
Taking oral dietary supplements of epigallocatechin-3-gallate (EGCG) — an antioxidant in green tea — may stop and reverse the pro-fibrotic (scarring) state of the lungs of people with idiopathic ...
Trevi Therapeutics plans to launch two pivotal Phase 3 clinical trials to continue testing Haduvio (nalbuphine extended-release) as a treatment for people with idiopathic pulmonary fibrosis (IPF) who ...
The oral therapy Jascayd (nerandomilast) has been approved in the European Union for adults with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF). The marketing ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results